Clinical Research Center, Department of Internal Medicine, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran.
Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Int Immunopharmacol. 2021 Dec;101(Pt B):108257. doi: 10.1016/j.intimp.2021.108257. Epub 2021 Oct 16.
Recently, the medications used for the severe form of the coronavirus disease-19 (COVID-19) therapy are of particular interest. In this sense, it has been supposed that anti-VEGF compounds would be good candidates in the face of "cytokine storm" and intussuscepted angiogenesis due to having an appreciable anti-inflammatory effect. Therefore, they can be subjected to therapeutic protocols to manage acute respiratory distress syndrome (ARDS). Since the compelling evidence emphasized that VEGFs contribute to the inflammatory process and play a mainstay role in disease pathogenesis, in this review, we aimed to highlight the VEGF's plausible participation in the cytokine storm exacerbation in COVID-19. Next, the recent clinical advances regarding the anti-VEGF medications, including humanized monoclonal antibody, immunosuppressant, a tyrosine kinase inhibitor, and a cytokine inhibitor, have been addressed in the setting of COVID-19 treatment in critically ill patients. Together, retrieving the increased level of VEGF subsets, as well as antagonizing VEGF related receptors, could be helpful for the treatment of COVID-19, especially in those suffering from ARDS.
最近，用于治疗严重新型冠状病毒病 2019（COVID-19）的药物特别受到关注。在这种情况下，有人认为抗血管内皮生长因子（VEGF）化合物在面对“细胞因子风暴”和“套叠性血管生成”时可能是很好的候选药物，因为它们具有显著的抗炎作用。因此，它们可以用于治疗急性呼吸窘迫综合征（ARDS）的方案中。鉴于强有力的证据强调了 VEGF 有助于炎症过程，并在疾病发病机制中起主要作用，在本综述中，我们旨在强调 VEGF 可能参与 COVID-19 中细胞因子风暴的加剧。接下来，我们探讨了针对 COVID-19 危重症患者治疗的抗 VEGF 药物的最新临床进展，包括人源化单克隆抗体、免疫抑制剂、酪氨酸激酶抑制剂和细胞因子抑制剂。总之，检测 VEGF 亚群的水平升高，并拮抗 VEGF 相关受体，可能有助于 COVID-19 的治疗，特别是对 ARDS 患者。
